| 厄洛替尼和塞来昔布联合应用对人肺腺癌 A549细胞放射增敏的研究 |
| |
| 引用本文： | 孙健,刘宁波,庄洪卿,赵路军,袁智勇,王平. 厄洛替尼和塞来昔布联合应用对人肺腺癌 A549细胞放射增敏的研究[J]. 中华放射医学与防护杂志, 2012, 32(2): 186-190 |
| |
| 作者姓名： | 孙健 刘宁波 庄洪卿 赵路军 袁智勇 王平 |
| |
| 作者单位： | 300060,天津医科大学附属肿瘤医院放疗科天津市肿瘤防治重点实验室 |
| |
| 摘 要： | 目的 探讨联合应用厄洛替尼和塞来昔布阻断表皮生长因子受体和环氧化酶-2受体对人肺腺癌A549细胞株的放射增敏效应及机制.方法 四甲基偶氮唑盐(MTT)比色法检测厄洛替尼和塞来昔布的IC20作为后续实验浓度.体外培养克隆形成实验检测厄洛替尼和塞来昔布联合或不联合X射线对人肺腺癌A549细胞的作用,计算其存活分数,绘制细胞存活曲线.流式细胞术检测细胞凋亡和细胞周期的变化,Western blot检测Akt和pAkt的表达.结果 厄洛替尼和塞来昔布的IG20分别为(5.15 ±0.14)和(40.32±1.26) μmol/L.照射+联合用药组的Dq、D0及SF2均明显低于单纯照射组、照射+塞来昔布组及照射+厄洛替尼组(t=6.62,P＜0.05)；照射+联合用药组、照射+厄洛替尼组和照射+塞来昔布组的SER为2.217、1.503和1.299.厄洛替尼和塞来昔布与射线联合作用后,使S期细胞比例减少,联合用药组作用更明显.药物作用前后及药物增敏照射后Akt在蛋白表达水平没有明显改变；塞来昔布和厄洛替尼均能抑制pAkt的表达,照射能够略提高pAkt蛋白的表达,与单纯照射组相比,塞来昔布或厄洛替尼联合照射组pAkt蛋白的表达减低,两药联用并联合照射组pAkt蛋白的表达最低(t=4.89,P＜0.05).结论 厄洛替尼和塞来昔布各自均有放射增敏作用,两药联合应用可以进一步提高放射增敏效应.其机制涉及到使细胞周期中对射线不敏感的S期细胞减少到最低,并进一步增强了射线诱导的凋亡.
|
| 关 键 词： | 塞来昔布 厄洛替尼 肺腺癌细胞 放射增敏 |
| 收稿时间： | 2010-05-19 |
Enhancement of radiation sensitivity by erlotinib and celecoxib in A549 human lung cancer cell line |
| |
| SUN Jian,LIU Ning-bo,ZHUANG Hong-qing,ZHAO Lu-jun,YUAN Zhi-yong and WANG Ping. Enhancement of radiation sensitivity by erlotinib and celecoxib in A549 human lung cancer cell line[J]. Chinese Journal of Radiological Medicine and Protection, 2012, 32(2): 186-190 |
| |
| Authors: | SUN Jian LIU Ning-bo ZHUANG Hong-qing ZHAO Lu-jun YUAN Zhi-yong WANG Ping |
| |
| Affiliation: | Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China;Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tainjin 300060, China |
| |
| Abstract: | |
| |
| Keywords: | Celecoxib|Erlotinib|Lung adenocarcinoma|Radiosensitization |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息 |
|
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文 |
|
